Kiniksa Pharmaceuticals Reports 55.5% Revenue Growth to $214.3 Million in Latest Quarter

Kiniksa Pharmaceuticals International, plc reported significant financial growth in its latest quarterly results, with total revenue reaching $214.3 million for the three months ended March 31, 2026, compared to $137.8 million during the same period in 2025. This 55.5% increase was primarily driven by higher sales of its product ARCALYST, which generated $214.3 million in product revenue, up from $137.8 million a year earlier. The company also reported a net income of $22.6 million, a substantial rise from $8.5 million in the previous year, resulting in a basic net income per share of $0.30, compared to $0.12 in the prior year.

Operating expenses for Kiniksa increased to $185.0 million from $124.5 million year-over-year, reflecting higher costs associated with collaboration expenses, which rose to $75.6 million from $43.8 million, and selling, general, and administrative expenses, which increased to $61.2 million from $43.5 million. Research and development expenses also grew to $27.5 million, up from $19.3 million, largely due to increased investment in the KPL-387 program, which saw direct costs rise significantly as the company advanced its clinical trials.

In terms of operational developments, Kiniksa has been actively expanding its product pipeline. The company is progressing with KPL-387, an investigational treatment for recurrent pericarditis, with plans to initiate a pivotal Phase 3 clinical trial by the end of 2026. Additionally, KPL-1161, another investigational asset, is expected to enter Phase 1 trials by the end of 2026. The company is also engaged in a technology transfer of ARCALYST manufacturing to Samsung Biologics, with the FDA accepting a supplemental biologics license application related to this transfer.

Kiniksa's cash position remains strong, with cash, cash equivalents, and short-term investments totaling $468.1 million as of March 31, 2026. The company anticipates that its current cash balance and expected cash inflows from operations will be sufficient to meet its operating plans for at least the next 12 months. Looking ahead, Kiniksa is focused on advancing its clinical programs and expanding its market presence, particularly in the recurrent pericarditis space, while managing its operational costs effectively.